We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Roche has unveiled new five-year data from three Phase 3 open-label extension studies investigating the efficacy of Ocrevus (ocrelizumab) in the treatment of relapsing